This filing is administrative and does not change the company's financial position. The key risk is the expired equity plan — without shareholder approval of a new plan, the company cannot grant equity incentives, which may affect retention. The recent auditor change (Deloitte → RJI) and the $2.1M January 2026 inducement warrant exercise are more material events to monitor.
Price Chart
Executive Summary
Arcadia Biosciences filed Amendment No. 1 to its 2025 10-K solely to add Part III information (director/officer details, executive compensation, beneficial ownership, related party transactions, and auditor fees) that was previously omitted pending a proxy statement. The amendment does not restate financials or update any Part I/II information. This filing follows the recent dismissal of Deloitte & Touche and appointment of a new auditor, and the company's equity compensation plans have expired with no replacement yet approved.
Key Facts
- Amendment adds Part III items (10-14) to the 2025 10-K; no financial restatement or change to prior financial statements.
- Deloitte & Touche LLP was the auditor for FY2025; audit fees were $892,001 in 2025 vs. $573,555 in 2024.
- Equity compensation plans (2015 Plan, ESPP) expired in 2025; no new plan has been approved by shareholders.
- Two 5% holders: Sabby Volatility Warrant Master Fund (9.9%) and Armistice Capital Master Fund (9.9%) hold via preferred investment options with 9.99% beneficial ownership caps.
- CEO Thomas Schaefer also serves as Interim CFO; total 2025 compensation was $300,001 (salary only, no bonus paid).
- Insider trading policy filed as Exhibit 19.1.
Financial Impact
No financial statement impact; amendment is administrative. Audit fees rose to $892,001 in 2025 from $573,555 in 2024.
Risk Factors
- No active equity incentive plan — inability to grant stock options or awards to executives/directors could impair talent retention.
- Auditor change from Deloitte to a smaller firm (RJI) following material weakness and going concern disclosures increases financial reporting risk.
- Heavy dilution from outstanding warrants/options: 231,839 shares under equity plans plus 1,617,190 new investment options issued in January 2026.
- Market cap of ~$2M with $5.7M public float — micro-cap volatility and potential Nasdaq compliance risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001193125-26-197315 |
| Document: 0001193125-26-197315-index.html | 0001193125-26-197315 |
| Document: 0001193125-26-197315.txt | 0001193125-26-197315 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | SC 13G | $0.2800 | awaiting T+60 | — | $0.1511 (−46.04%) |
Sep 15, 2026 5w ago | 8-K | $0.4310 | awaiting T+60 | — | $0.1511 (−64.94%) |
Jul 9, 2026 15w ago | EFFECT | $0.6755 $0.2882 | ▲ +57.34% | ▲ +58.97% | $0.1511 (+77.63%) |
Jul 2, 2026 16w ago | 8-K | $0.7330 $0.3080 | ▼ −57.98% | ▼ −61.55% | $0.1511 (−79.39%) |
Jun 26, 2026 17w ago | S-3 | $0.7190 $0.4480 | ▲ +37.69% | ▲ +42.08% | $0.1511 (+78.98%) |
Jun 15, 2026 18w ago | 8-K | $0.9183 $0.4797 | ▲ +47.76% | ▲ +48.77% | $0.1511 (+83.55%) |
Jun 12, 2026 19w ago | Press Release | $0.9183 $0.4797 | ▲ +47.76% | ▲ +48.77% | $0.1511 (+83.55%) |
Jun 12, 2026 19w ago | Press Release | $0.9180 $0.4530 | ▲ +50.65% | ▲ +51.31% | $0.1511 (+83.54%) |
May 14, 2026 23w ago | 8-K | $0.9560 $0.6699 | ▲ +29.93% | ▲ +34.44% | $0.1511 (+84.19%) |
Apr 30, 2026 25w ago | 10-K/A | $1.12 $0.6300 | ▼ −43.75% | ▼ −46.82% | $0.1511 (−86.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers